The global opioid use disorder market is estimated to grow at a CAGR of around 7% during the forecast period. Opioids are natural or synthetic type chemicals, interact with opioid receptors on the nerve, resulting in it reduce feelings of pain. Opioids are of two types that are prescribed and non-prescribed. Prescribed drugs are used to treat acute pain, such as pain from an injury, post-surgery pain, and others. Some of the non-prescribed opioids are heroin, morphine, and others. Excessive use of opioids leads to opioid use disorder (OUD). It is a lifelong disorder. OUD is of two types, which are patients addicted to prescribed opioids and patients who are addicted to non-prescribed opioids. For these OUDs, effective treatments are available in the market, Medication-assisted treatment (MAT) is one of them.

High side effects of opioids and the rising frequency of opioid use disorder patients are the major factors that are driving the global opioid use disorder market. According to the Centers for Disease Control and Prevention (CDC), in 2016 in the US, 2.1 million people were suffering from opioid use disorder related to prescribed opioids and 262,000 were suffering from opioid use disorder related to heroin. As per the American Psychiatric Association, in 2017, in the US, over 31,000 people died from an opioid overdose, both prescribed and non-prescribed, among them over 16,000 people died from the overdose of heroin and 15,000 people died from the overdose of prescribes opioids. Sometimes prescribed opioids are more harmful than the non-prescribed opioids. Fentanyl is 100 times more potent than morphine and 50 times more potent than heroin. Such a high prevalence of opioid use disorder is creating demand for OUD drugs to manage the disorder. 

Counseling, opioid replacement therapy, and gradual discontinuation of opioids are some of the non-medication therapies that are used to prevent OUD. Opioid replacement therapy or Opioid substitution therapy (OST) is a type of harm reduction initiative. It is an alternate prescribed medicine for those patients, who are addicted tonon-prescribed opioids such as heroin. In 2009, WHO released guidance to make OST, the key focus of the treatment of OUD. During the Corona outbreak, the opioid epidemic became worse. In a recent publication of the National Public Radio (NPR), it is estimated that a large number of people could die due to opioid overdose. This is an opportunity in the growth of the global opioid use disorder market. Some of the side effects of OUD is restraining market growth. Side effects are nausea, vomiting, and constipation, muscle aches and cramps, cravings, inability to sleep, distress and irritability, fever, and others.

Segmentation

The global opioid use disordermarket is segmented based on Drug type. Based on drug type, the market is segmented into Methadone, Buprenorphine, and Naltrexone. And Buprenorphine is segmented into Bunavil, Suboxone, Zubsclv, Sublocade, and Others.

The buprenorphine segment held a significant share in the drug segment

FDA-approved Methadone, Buprenorphine, and Naltrexone medications are mainly used to treat OUD, these all are safe and effective in the treatment of OUD. Among these, Buprenorphine is the largest revenue-generating segment. Buprenorphine was approved by FDA in October 2002. FDA approved Buprenorphine products are Bunavail (buprenorphine and naloxone), Suboxone (buprenorphine and naloxone), Zubsolv (buprenorphine and naloxone), Sublocade and others. Buprenorphine produces effects such as euphoria or respiratory depression at low to moderate doses, though these effects are weaker than full opioid agonists such as methadone and heroin. Suboxone film is the most used Buprenorphine OUD. Suboxone film has high efficiency in managing opioid addiction.

Global Opioid Use Disorder Market Share by Drug Type, 2018 (%)

Regional Outlook

North America is expected to have a significant market share in the global opioid use disorder market. Key factors that are driving the market include awareness among the public, availability of proper healthcare infrastructures, and the presence of the major players offering innovative opioid use disorder in the market. Besides government-sponsored policies and awareness campaigning programs are also propelling the North American opioid use disorder market. For instance, in October 2017, in the US, the CDC launched the Rx Awareness campaign, to aware the public about the side effects of the overdose of opioids.

As per CDC data over 12.5 million people have misused prescribed opioids in 2015, and between 1999 and 2015, over 183,000 people died due to overdose of prescribed opioids in the US. Every year Rx Awareness campaign began running from September 25, and it continues for 14 weeks in Ohio, Kentucky, Massachusetts, and New Mexico cities. Moreover, the Asia-Pacific region is the fastest-growing astaxanthin market, owing to the rise of large numbers of the patient, growing economy, and increasing health awareness is driving the market.

Global Opioid Use Disorder Market Growth, by Region 2019-2025

Competitive Landscape

The major players providing opioid use disorder (OUD) drugs include Indivior PLC, BioDelivery Sciences International, Inc., Alkermes, PLC, Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corp, Camurus AB, Hikma Pharmaceuticals PLC, and others. Mergers and acquisitions and product launches are considered as crucial strategies adopted by the market players to expand market share and gain a competitive advantage. For instance, in January 2020, Titan Pharmaceuticals, Inc. launched Probuphine, it is used for the treatment of OUD and it is the only subdermal implant designed, that deliver buprenorphine continuously for six months.In October 2017, Indivior PLC got FDA approval for its drug SUBLOCADE injection, it is used to serve opioid use disorder. It is the first and only once-monthly buprenorphine.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global opioid use disorder market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.